Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 15, 2021

Eisai’s anti-cancer agent LENVIMA receives orphan drug designation

Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine body cancer.

Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine body cancer.

LENVIMA, which obtained the designation from the Ministry of Health, Labour and Welfare (MHLW), is an orally available multiple receptor kinase inhibitor discovered by Eisai.

It inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4).

Furthermore, LENVIMA inhibits other kinases implicated in pathogenic angiogenesis, tumour growth and cancer progression in addition to their normal cellular functions.

As part of the multi-centre, randomised, open-label Phase III Study 309/KEYNOTE-775, LENVIMA was evaluated in combination with KEYTRUDA in patients with advanced endometrial cancer after at least one prior platinum-based regimen in Japan, the US, the EU and other countries.

The company stated that LENVIMA together with KEYTRUDA has met the overall survival (OS) and progression-free survival (PFS), namely its dual primary endpoints.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

It also met the secondary efficacy endpoint of the objective response rate (ORR) in the trial.

The company is now preparing to submit an application for additional indications depending on the trial results in various countries globally, including Japan.

It seeks to address the diverse needs and increase benefits for patients with cancer and proposes to expand LENVIMA’s potential clinical benefits for cancer treatment.

Over 30,000 people in Japan are infected with uterine body cancer, with more than 90% of the disease expected to occur in the endometrium.

In 2018, Eisai entered a strategic collaboration with US-based pharmaceutical company Merck & Co for the worldwide co-development and co-commercialisation of LENVIMA.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU